The company completes its license agreement with Texas and hires Mark Standeford.

Cardiovate, a biomedical technology spin-out, has completed a patent and technology license agreement with the University of Texas at San Antonio (UTSA), and the University of Texas Health Science Centre San Antonio. The agreement lets the company continue its research and product development.

At the same time, the company has also announced the hiring of Mark Standeford. He will take over as CEO. Standeford has 27 years of experience in the medical device industry, having developed and commercialised more than…